These data are consistent with the recent findings illustrating that the combination of KIT and FGFR inhibition increased the growth inhibition in IM-sensitive GIST cell lines (e.g., GIST-T1 and GIST882) and improved efficacy in patient-derived GIST xenografts [11]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.